USA flag logo/image

An Official Website of the United States Government

Refanalin for Liver Transplantation

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65866
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
AA014718
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANGION BIOMEDICA CORPORATION
51 Charles Lindbergh Blvd Uniondale, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2004
Title: Refanalin for Liver Transplantation
Agency: HHS
Contract: 2R44AA014718-02
Award Amount: $1,398,781.00
 

Abstract:

DESCRIPTION (provided by applicant): Orthotopic liver transplantation is the most effective treatment for patients with end-stage liver disease. Ischemia-reperfusion injury associated with the retrieval, storage and transplantation of livers is a major immune-independent factor adversely affecting early graft function, and limiting long-term graft survival. Marginal donors livers, including steatotic livers, are even more susceptible to ischemia-reperfusion injury, and often fail transplantation. Scatter factor/hepatoyte growth factor is a hepatotrophic factor with significant hepatoprotective activity. However its clinical use is limited by the logistical difficulties associated with its administration. We have identified Refanalin, an organic small molecule scatter factor/hepatocyte growth factor mimetic, with significant cytoprotective activity. In animal models of organ-specific ischemic injury, Refanalin attenuates infarct size and improves function. In in vivo global hepatic ischemia-reperfusion, Refanalin reduces hepatic injury, attenuates hepatocyte apoptosis and necrosis and preserves hepatic ultrastructure. The present Phase II proposal explores the therapeutic potential of Refanalin in clinically relevant models of orthotopic liver transplant. By attenuating allograft dysfunction and preventing allograft failure, Refanalin can reduce recipient morbidity and mortality. By attenuating ischemia-reperfusion injury in the marginal liver, Refanalin can salvage an otherwise discarded organ, and increase the donor pool.

Principal Investigator:

Weizhong Cai
5165621140
wcai@angion.com

Business Contact:

Itzhak Goldberg
5168696400
GOLDBERG@ANGION.COM
Small Business Information at Submission:

ANGION BIOMEDICA CORPORATION
ANGION BIOMEDICA CORP 350 COMMUNITY DR, RM 129 MANHASSET, NY 11030

EIN/Tax ID: 113430072
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No